Denali Therapeutics Inc. (DNLI) EPS Estimated At $-0.19

July 14, 2018 - By Sheila Anderson

Analysts expect Denali Therapeutics Inc. (NASDAQ:DNLI) to report $-0.19 EPS on August, 10.After having $-0.26 EPS previously, Denali Therapeutics Inc.’s analysts see -26.92 % EPS growth. The stock decreased 1.83% or $0.27 during the last trading session, reaching $14.49. About 156,089 shares traded. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company has market cap of $1.37 billion. The firm offers leucine-rich repeat kinase 2 inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Another recent and important Denali Therapeutics Inc. (NASDAQ:DNLI) news was published by which published an article titled: “2 Biotech Stocks at New Lows. Can They Recover?” on July 05, 2018.

Denali Therapeutics Inc. (NASDAQ:DNLI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.